Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?

Acta Neurologica Scandinavica

Volumn 126, Issue S194, 2012, Pages 10-18

  Trinka, E ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Antiepileptic drug; Comorbidity; Efficacy; Epilepsy; Genotyping; Pharmacokinetics; Quality of life; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ORAL CONTRACEPTIVE AGENT; PSYCHOTROPIC AGENT; WARFARIN;

ACNE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; COMORBIDITY; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; GENETIC SCREENING; HEALTH STATUS; HUMAN; HYPONATREMIA; LIFESTYLE; LIVER FAILURE; MEDICAL LITERATURE; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PREGNANCY; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SEIZURE; SIDE EFFECT; TERATOGENICITY; WEIGHT CHANGE; RISK; TREATMENT OUTCOME;

ANTICONVULSANTS; EPILEPSY; GENETIC TESTING; HUMANS; QUALITY OF LIFE; RISK; TREATMENT OUTCOME;

EID: 84868091762     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12015     Document Type: Review

References (95)

1. Arzimanoglou A, Ben-Menachem E, Cramer J, Glauser T, Seeruthun R, Harrison M. The evolution of antiepileptic drug development and regulation. Epileptic Disord 2010;12:3-15.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
3. Trinka E, Martin F, Luef G, Unterberger I, Bauer G. Chronic epilepsy with complex partial seizures is not always medically intractable - a long-term observational study. Acta Neurol Scand 2001;103:219-25.
4. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007;62:382-9.
5. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62:375-81.
6. Bautista RE, Glen ET. Seizure severity is associated with quality of life independent of seizure frequency. Epilepsy Behav 2009;16:325-9.
7. Sancho J, Iváñez V, Molins A, López Gómez V, Masramón X, Pérez M. Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 2010;19:409-13.
8. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006;47:1253-84.
9. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 1997;38:353-62.
10. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997;6:87-93.
11. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 2005;181:30-5.
12. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat 2007;3:117-31.
13. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009;27:993-1002.
14. Azar NJ, Abou-Khalil BW. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Semin Neurol 2008;28:305-16.
15. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
16. Trinka E, Dilitz E, Unterberger I et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002;249:1417-22.
17. Asconapé JJ. The selection of antiepileptic drugs for the treatment of epilepsy in children and adults. Neurol Clin 2010;28:843-52.
18. Lagae L. The need for broad spectrum and safe anti-epileptic drugs in childhood epilepsy. Acta Neurol Belg 2009;109:167-70.
19. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26:423-32.
20. Perucca E, Levy RH. General principles. Combination therapy and drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002:96-102.
21. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
22. Gidal BE. Pharmacokinetics of the new antiepileptic drugs. Am J Manag Care 2001;7(7 Suppl.):S215-20.
23. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55.
24. Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav 2009;15:56-65.
25. Kessler RC, Lane MC, Shahly V, Stang PE. Accounting for comorbidity in assessing the burden of epilepsy among US adults: results from the National Comorbidity Survey Replication (NCS-R). Mol Psychiatry 2012;17:748-58.
26. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
27. Dutton C, Foldvary-Schaefer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management. Int Rev Neurobiol 2008;83:113-34.
28. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010;8:254-67.
29. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
30. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique JAMA 1989;261:3273-7. Erratum: JAMA 1989;262:1472.
31. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behaviour - a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991;41:589-92.
32. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-7.
33. Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13:914-20.
34. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997;20:1512-7.
35. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
36. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33.
37. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002;3:338-42.
38. Hovinga CA, Asato MR, Manjunath R et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008;13:316-22.
39. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008;49:446-54.
40. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008;71:1572-8.
41. Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia 2009;50:501-9.
42. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia 2007;48(Suppl. 9):42-5.
43. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336-44.
44. Pompili M, Girardi P, Ruberto A, Tatarelli R. Suicide in the epilepsies: a meta-analytic investigation of 29 cohorts. Epilepsy Behav 2005;7:305-10.
45. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007;6:693-8.
46. Ciechanowski P, Chaytor N, Miller J et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 2010;19:225-31.
47. Chaytor N, Ciechanowski P, Miller JW et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav 2011;20:545-9.
48. Gilliam F, Penovich PE, Eagan CA et al. Conversations between community-based neurologists and patients with epilepsy: results of an observational linguistic study. Epilepsy Behav 2009;16:315-20.
49. Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006;5:399-405.
50. Kanner AM. Advances in epilepsy: new perspectives on new-onset epilepsy, comorbidities, and pharmacotherapy. F1000 Med Rep 2010;2:51.
51. Cramer JA, Steinborn B, Striano P et al. Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand 2011;124:13-21.
52. Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Healthc Patient Saf 2011;3:15-20.
53. Beerhorst K, Huvers FC, Renier WO. Severe early onset osteopenia and osteoporosis caused by antiepileptic drugs. Neth J Med 2005;63:222-6.
54. Nakken KO, Taubøll E. Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 2010;9:561-71.
55. Carbone LD, Johnson KC, Robbins J et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res 2010;25:873-81.
56. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008;70:1586-93.
57. Mintzer S, Skidmore CT, Abidin CJ et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009;65:448-56.
58. Elliott JO, Lu B, Shneker B, Charyton C, Layne Moore J. Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav 2009;14:125-9.
59. Marini C, Scheffer IE, Nabbout R et al. The genetics of Dravet syndrome. Epilepsia 2011;52(Suppl. 2):24-9.
60. Specchio N, Marini C, Terracciano A et al. Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations. Epilepsia 2011;52:1251-7.
61. Kollberg G, Moslemi AR, Darin N et al. POLG1 mutations associated with progressive encephalopathy in childhood. J Neuropathol Exp Neurol 2006;65:758-68.
62. Joensuu T, Kuronen M, Alakurtti K et al. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 2007;15:185-93.
63. Singh S, Satishchandra P, Shankar SK, Ganesh S. Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum Mutat 2008;29:E1-12.
64. Delgado-Escueta AV, Bourgeois BF. Debate: does genetic information in humans help us treat patients? PRO - genetic information in humans helps us treat patients. CON - genetic information does not help at all Epilepsia 2008;49(Suppl. 9):13-24.
65. Saneto RP, Lee IC, Koenig MK et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010;19:140-6.
66. Isohanni P, Hakonen AH, Euro L et al. POLG1 manifestations in childhood. Neurology 2011;76:811-5.
67. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
68. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43.
69. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006;67(12 Suppl. 4):S56-8.
70. Meador KJ, Penovich P, Baker GA et al.; NEAD Study Group. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009;15:339-43.
71. Ozkan H, Cetinkaya M, Köksal N, Yapici S. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med 2011;24:521-4.
72. Tomson T, Battino D, Bonizzoni E. et al.; EURAP Study Group Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17.
73. Meador KJ, Baker GA, Browning N. et al.; NEAD Study Group Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-605.
74. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002.
75. Krishnamurthy KB. Pregnancy and epilepsy:update on pregnancy registries. Curr Treat Options Neurol 2008;10:246-52.
76. Isojärvi JI. Reproductive dysfunction in women with epilepsy. Neurology 2003;61(6 Suppl. 2):S27-34.
77. Luef GJ, Lechleitner M, Bauer G, Trinka E, Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-8.
78. Luef GJ, Waldmann M, Sturm W et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55:729-32.
79. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 2006;29:1-21.
80. Johnston A, Smith PE. Epilepsy in the elderly. Expert Rev Neurother 2010;10:1899-910.
81. Tallis R, Boon P, Perucca E, Stephen L. Epilepsy in elderly people: management issues. Epileptic Disord 2002;4(Suppl. 2):S33-9.
82. Trinka E. Epilepsy: comorbidity in the elderly. Acta Neurol Scand Suppl 2003;180:33-6.
83. Copeland LA, Ettinger AB, Zeber JE, Gonzalez JM, Pugh MJ. Psychiatric and medical admissions observed among elderly patients with new-onset epilepsy. BMC Health Serv Res 2011;11:84.
84. Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand 2011;124:223-37.
85. Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother 2011;9:405-12.
86. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-80.
87. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976-8.
88. Arif H, Buchsbaum R, Weintraub D et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9.
89. Berger TG, Steinhoff M. Pruritus in elderly patients - eruptions of senescence. Semin Cutan Med Surg 2011;30:113-7.
90. Kerr M, Kluger G, Philip S. Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord 2011;13(Suppl. 1):S15-26.
91. Paolicchi JM. Epilepsy in adolescents: diagnosis and treatment. Adolesc Med 2002;13:443-59.
92. Sheth RD. Adolescent issues in epilepsy. J Child Neurol 2002;17(Suppl. 2):2S23-7.
93. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-91.
94. Sheth RD, Gidal BE. Optimizing epilepsy management in teenagers. J Child Neurol 2006;21:273-9.
95. Benavente-Aguilar I, Morales-Blánquez C, Rubio EA, Rey JM. Quality of life of adolescents suffering from epilepsy living in the community. J Paediatr Child Health 2004;40:110-3.